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ABSTRACT
OBJECTIVE: To determine whether or not the Phosphodiesterase inhibitors drug Sildenafil
Citrate is safe and effective treatment for Pulmonary Hypertension in adults
STUDY DESIGN: reviewed primary research materials published in English language between
1996 and 2009
DATA SOURCES: Randomized, controlled, double-blind clinical trials found using OVID,
MEDLINE, and Cochrane data bases
OUTCOME MEASURED: trials measured 6-minute walking distance improvement,
hemodynamic measurements to asses vascular resistance, peak VO2
RESULTS: two randomized trials included in this review showed Sildenafil is effective in
treating PAH. The trials showed patients had an improvement their 6-minute walking distance,
quality of life improvement, and decreased vascular resistance. A trial conducted by Shim et al
was in conclusive needing further research as it is one of the only trials that tried to determine the
effect of Sildenfil in patients who are undergoing cardiac surgery
CONCLUSIONS: Sidenfil provides symptomatic relief with little side effects in patients
suffering from PAH. Two of the researches showed that sidenfil did have an efficacy in treating
PAH by decreasing vascular resistance.
KEY WORDS: Sildenafil, Viagra, pulmonary hypertension, pulmonary atrial hyper tension
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INTRODUCTION
Pulmonary Hypertension is a very rare disease that is caused by an increase in pressure in
pulmonary arteries. CDC reported in 2002 Pulmonary artery hypertension (PAH) was the cause
of 15,668 deaths and 260,000 hospitalizations in the U.S. PAH affects primarily older women;
however, it is seen in both male and female of all ages and races 5. Prior to 1995 the life
expectancy of person with PAH was 3years since then average life expectancy has improved due
to better treatment options. The invention and use of pulmonary artery catheters (Swan-Ganz)
have enabled clinicians to diagnose and treat PAH by measuring the pulmonary capillary
pressure and thereby determining the pulmonary vascular resistance. This created the opportunity
for early diagnosis/treatment and as a result prolonging life expectancy for those diagnosed.
Normally the average pulmonary artery pressure is 25 mmHg at rest or 30 mmHg during
physical activity. The world health organization divides PAH into five categories. The first
category contains causes of PAH that have unknown origin, inherited, congenital or from HIV
infection. Second group consist of PAH with heart disease. Third is PAH that coexist with lung
diseases such as COPD. Fourth deals with PAH caused by blood clotting diseases such as
pulmonary emboli polycythemia, or sickle cell anemia and fifth group includes causes such as
Sarcoidosis, Langerhans cell Histioytosis, or tumor. In general, group one is considered primary
PAH and those from 2nd -5th are secondary causes of PAH.
Patients with PAH present with exertional dyspnea, fatigue on exertion, light
headedness/weakness due to hypoxia and if leg edema develops it is often a sign of right sided
heart failure. If PAH is not diagnosed and treated early, patients are more likely to develop CorPulmonale. Normally, pressure in the pulmonary arteries is low allowing the RV to pump blood
in to the lungs with little effort. However, in patients with PAH due to narrowing of the
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pulmonary artery the RV has to compensate by using forceful contractions in order to overcome
pulmonary artery resistance which leads to RV enlargement. Moreover, PAH increases RV
susceptibility to ischemic injury and patients with right sided heart failure are at high risk for
pulmonary embolism. Definite diagnosis of PAH is made by pulmonary catheterization (swanz
ganz cath) by measuring pressure in the RV and the pulmonary artery. However, exercise
oximetry is a helpful diagnostic method as well. A fall in oxygen saturation without a history of
lung parencymal disease is a strong indication for pulmonary vascular disease. In addition Chest
x-ray can be used to detect cardiomegaly and Echocardiograpy is used to detect RV and LV
function and valvular insufficiency.
Arteries and lesions in the arterioles are the cause of the hypertension. Pulmonary
endothelial dysfunction that leads to impaired production of vasodilators, such as nitric oxide,
Prostacyclin, and over-expression of vasoconstrictors, such as Endothelin-1. These disease
process lead to narrowing of the arteries. There are three classes of medications that are currently
approved by the FDA. They are Prostacyclin (PGI2) analogues (Epoprostenol, Treprostinil, and
Iloprost), Endothelin Receptor Antagonists (ERA) (Bosentan, Ambrisentan, and Sitaxsentan) and
Phosphodiesterase inhibitors (PDEI) (Sildenafil, Tadalafil) 4. Other treatments include,
Anticoagulants, diuretics, Digoxin, supplemental oxygen, OR calcium-channel blockers. If
medication fails, Lung transplant is considered. The initial therapy of choice depends on cause of
disease. Patients with Positive vasodilator response and WHO class I-III can be managed by
CCB. Those with Negative vasodilator response or WHO class II or III are initiated with ERA or
PDEI treatment.

Objective:
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The objective of this systematic review is to determine whether or not the
Phosphodiesterase inhibitors drug Sildenafil Citrate is safe and effective treatment for Pulmonary
Hypertension in adults

METHODS:
The studies used for this review were selected based on the following criteria. The patient
population was over the age of 18 and suffering from PAH. The intervention used was oral
Sildenafil. The treatment groups were compared to placebo groups who received water pills. The
outcomes measured were improvement of exercise capacity, improvement of 6minute walk,
quality of life, hemodynamic measurements, and prevention of RVHF; all of these can qualify as
patient oriented evidence that matter (POEM). All the three studies were randomized double
blind, placebo-controlled
In research conducted by Shim et al, Fifty three patients with scheduled valvular heart
surgery and systolic RV pressure >50mmHg and pulmonary pressure >30mmHgwere enrolled
into the trial. Participants were randomly divided and given 50mg Sildenafil (n=26) or Placebo30ml sterile water (n-27) 10minutes before induction of anesthesia. Ten minutes before and five
minutes after induction of anesthesia and 30 and 60 minutes after medication hemodynamic
measurements were calculated. Badesch et al run a 12-week study on 278 PAH patients with 84
subset of patients with connective tissue disease (CTD-PAH) with mean Pulmonary pressure
>25mmHg and pulmonary artery wedge pressure <15mmHg at rest. Patients were randomly
assigned into treatment and placebo groups. Those in treatment groups received Sildenafil at
doses of 20mg TID, 40mg TID, or 80mg TID. Exercise capacity, Hemodynamic Measures and
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WHO functional class and tolerability were assessed at week 4, 8 and 12weeks. Patients were
excluded if they had a 6-minute walk distance (6MWD) of ≤ 100 m or ≥ 450 m.
Thirty four patients over the age of 18 who have chronic Heart failure despite standard
HF therapies with secondary PAH (arterial pressure over 25mmHg) were enrolled in Lewis et al
trial. Patients were randomized to 12-weeks treatment of Sildenafil (25-75mg orally TID) or
placebo. Medication was initiated at 25mg then titrated up to 75mg TID over the course of every
2weeks. Cardiopulmonary exercise testing was done before and after treatment in order to
measure peak VO2. 22-gauge catheter was placed in the radial artery for continues measurement
of mean arterial pressure and blood gas measurements were done at 1-minute intervals during
cardiopulmonary exercise. Cardiac output at rest and during excersis was measured using Fick
Oxygen technique.
Key words used in searches were Pulmonary Hypertension, pulmonary arterial
hypertension, pulmonary hypertension, Sildenafil, Viagra. All articles were published in an
English langue in peer-reviewed journals. This author personally did the article search in OVID
Medline and Cochran database. Inclusion criteria were: patients over the age of 18, randomized,
POEM, RCT’s, articles published between 1996 and the present and not used in any prior metaanalysis or systematic review publications. Exclusion criteria were: Patients under 18y.o,
Disease-oriented evidence (DOE) trials, studies published before 1996, and articles used in prior
meta-analysis or systematic review publications
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Study

Type

Shim,
2006
(1)

Badesch,
2007
(2)

Lewis,
2007
(3)

#
Pts

Age

Inclusion
Criteria

Exclusion Criteria

W/D

Intervention

Double blind 53
RCT

Mean
age 5357

Pts with
concomitant
pulmonary
hypertension
undergoing
valvular surgery
with pulmonary
arterial pressure
greater than
30mmHg

7

50mg Oral
Sildenafil given
10min before
anesthesia

Randomized, 278
double blind,
placebocontrolled
study
Randomized, 34
double blind,
placebocontrolled
study

Mean
50-56

Pts w/
Connective
tissue disease,
>18yo

Pts w/ preexisting
lung parenchymal
disease, coronary
artery occlusive
disease, hepatic or
renal disease, TR
of at least 2, or
NYHA functional
class of at least 3,
and pts taking
nitrates were
excluded.
Pts w/ 6-minute
walk distance
(6MWD) of ≤ 100
m or ≥ 450 m

5

Oral Sildenafil
in three dose
groups (20, 40,
80 Mg tid)

Mean
age 5462

>18 y.o. w/ ,
LVSD and
NYHA class II
to IV CHF
despite standard
HF therapies.
Pts w/
secondary PH
pressure >25
mm Hg

Pts w/ a noncardiac
limitation to
exercise,
provocable
ischemia,
hemodynamic
instability, or
ongoing nitrate
therapy

3

Oral Silddenafil
25-75mg 3xday

OUTCOMES MEASURED
Pulmonary hypertension causes right ventricular failure. If pulmonary hypertension rises,
RV is susceptible to ischemic injury. So the done by Shim et al tried measured systolic
pulmonary atrial pressure (SPAP), MPAP, Central venous pressure, RV ejection fraction, RV
end-systolic/diastolic volume index, and pulmonary vascular resistance index. In Badesch et al
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study the outcomes were measured using exercise capacity from base line and hemodynamic
measurements (mPAP, mean right atrial pressure (mRAP), cardiac output, and pulmonary
vascular resistance (PVR)).
Lewis et al measured Oxygen uptake (VO2), carbon dioxide output (VCO2), and
respiratory exchange ratio, cardiac output, systemic vascular resistance and PVR at rest and
during exercise. Right atrial, pulmonary aterial and pulmonary wedge pressure were measured
while patient was upright on bicycle or sitting during cardiopulmonary exercise. Also, 6minute
walk distance was measured at baseline, 6weeks and at 12week 6-min walk distance and mean
pulmonary arterial pressure was calculated. After completion of these measurements, patients
were given a questionnaire (21 questions to assess their quality of life) with scores ranging from
0-5 for each question and. Measured VO2 during exercise and at rest using Fick oxygen
Technique.

RESULTS
All three of the articles presented double blinded, randomized control trials. Shim et al
addressed the effects of Sildenafil citrate on patients with PAH who were undergoing vascular
heart surgery. The study had 53 participants with mean age of 57 for control groups and mean
age of 53 for control groups. Ratio of male to females was equal in both control and treatment
groups. Badesch et al conducted research on 278 patients with PAH and 84 subgroup of patients
with CTD-PAH. Of the 278 patients, 94 completed the study. Majority of the patients were
women, patients with scleroderma and those in factional category III. Most common non-dose
related sildenafil side effects noted among patients were Headache and epistaxis. During the
trial, 5 patients dropped out of the treatment group. Three patients died (cause of death: MI, PE,
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Urosepsis) and two patients discontinued due to lower leg edema and cirrhosis of the liver. None
of these deaths were attributed to treatment with sildenafil.
Lewis et al studied thirty four patients with LVSD in NYHA class II-IV with PAH were
enrolled in trial for 12 weeks. These participants had previously shown 2-4% increase in peak
VO2 after one time treatment of Sildenafil. In total, four patients withdrew from trial (two from
each group) and no deaths occurred. One patient from treatment group withdrew after elective
implantation of cardiac resynchronization device and second one due to ventricular tachycardia
with syncope. In placebo group, one patient withdrew due to pruritis and another due to
worsening HF. As with Badesch et al trial, the most common side effect noted in this trial was
headache. About 41% of patients treated with sildenafil complained of Headache. In addition, at
the end of the trial fewer patients in the treatment groups were hospitalized compared to those in
placebo group (P=0.046).
The data in shim et al study was presented in Continuous data form using x2 test. At T0
there was no significant hemodynamic variables difference from baseline between control and
treatment groups. At T30, SPAP, MPAP, and PVRI were significantly lower in sildenafil group
compared to control groups; moreover, SPAP and MPAP at T30 were significantly lower in
sildenafil group compared to baseline values. At T0 hemodynamic values are similar between all
groups with no statistical significance (SPAP: P=0 .07; MPAP: P= 0 .087; PVRI: P=0 .09).
There was little total significant difference between control and treatment groups with the
exception of PVRI. P value for PVRI was statistically significant difference between treatment
group and placebo group (P=0.04)
Patients in Badesch et al treated with Sildenafil showed had an increase in 6minute
walking distance compared to control groups after 12weeks of treatment with a mean increase of
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55m at the end of week 12. After 12 weeks of treatment the treatment group with 20mg had a
mean increase of 42m and those treated with 40mg had an increase of 36m and with 80mg of
Sildenafil there was an increase of 15m. Patients in treatment group showed an improvement in
WHO functional class following the 12-week treatment. Patients treated with 80mg of Sildenafil
had 42% changes, greater than the other two treatment groups. This data were converted from
“continuous data” form to “Dichotomous” data. Experimental event rate (EER) was 42%; this is
the percentage of patients who showed an improvement after treatment with 80mg of Sildenafil.
The Control event rate (CER) was 5%, meaning the % of patients who showed an improvement
in controlled group. From this numbers RRR and ARR were calculated. An absulute risk
reduction (ARR) of 0.37 and the Relative risk reduction (RRR) was 7.4. the number needed to
treat (NNT) was 2.7. Hemodynamic measurements only showed improvement in only those
treated with 20mg TID achieved a statstical significant change with P<0.01 of mPAP and p<0.05
of PVR
Measured exercise capacity of patients by measuring their peak VO2. Patients treated
with Sildenafil had VO2 increase from 12.2+0.7 to 13.9+1.0 mL/kg/ min with P=0.02; while vo2
did not change in placebo group. In addition patients in treatment groups had greater change in
their peak VO2 from base line compared to control group. Anothere variable measured was
cardiac output. Patiets treated with medication had an increase in CO. the increase in Peak VO2
in treatment group lead to an improvement in PVR (p=0.002) and RV ejection fraction (p=0.01).
patients had improved EVEF at rest and peak exercise (p=0.03; p=0.04 respectively); while no
change was observed in placebo group at the end of 12 weeks resting PVR (20+6%; P=0.02)
and in PVR/SVR (-16+6%; P=0.01) indicating sildenefil has a selective vasodilator effect.
Patients in intreatment groups had also an increase in their 6MWD by 62m (p=0.004). The study
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also measured patients quality of life by using a questioniar. NYHA cass improved in 53% of
sildenfil treatmentpatients while only 7% improved in placebo group (p=0.045). Patients
receiving medication saw a reduction in N-terminal BNP levels at week 12 compared to placebo
(p=0.11).

DISCUSSION
Sildenafil is the only FDA approved Phosphodiestrase inhibitor to PAH.
Phosphodiesterase Inhibitors works by slowing the metabolism of intracellular cGMP. cGMP is
activated by NO and Prostacyclins leading to relaxation of vascular smooth muscle. Sildenafil is
marketed under trade name Revatio for PAH and Viagra for erectile dysfunction. It peaks an
hour after first ingestion and has 3.7 hours of half life. It is associated with Headache and Visual
blurriness. Two trials by Levi et al and Badesch et al showed a statistically significant
improvement in outcomes they measured. In these studies, Sildenafil treatment improved
exercise capacity, Hemodynamic measurements and improved patients’ functional class in
Patients with CTD-PAH compared to placebo group. Also Systolic heart failure patients with
PAH that were enrolled in sildenafil treatment group had an improved exercise capacity, 6minute walking distance, improved quality of life and decreased hospital admission. However,
trial conducted on patients that were undergoing valvular heart surgery did not show statistically
significant difference between treatment and control groups. The most important clinical
significant of this trial was to determine the effect of sildenafil on homodynamic measurements
because this measurements directly reflect PAH. There by decreased pulmonary pressure can
preserve coronary perfusion leading to decreased complications due to RV ischemia and
subsequent RV dysfunction. Limitations of these three trials were their small sample size (it
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ranged from 34-53), short duration of trial period with the longest being 12wks and none of the
trials included comprehensive long-term treatment follow-up. Small sample sizes may be good
for limiting sample variables; however, larger data sizes give a more concrete and strong
correlations.
CONCLUSION
Although, treatment with sildenafil did not show efficacy in patients undergoing vascular
surgery, the other two studies done on CTD-PAH and Systolic heart failure patients showed
Sildenafil is effective in improving 6-MWD, quality of life and hemodynamic measurements.
Furthermore, compared to medications used for PAH, Sildenafil has fewer numbers of side
effects. The dilatory effect of Sildenafil leads to decreased vascular pressure which in turn
increases cardiac output and EF. The increase in cardiac output and EF has direct effect on
improving patients’ quality of life by decreasing dyspnea, fatigue and other symptoms. All the
studies measured atrial pressure to determine the effects of sildenafil; however, atrial pressure
depends on different variables. Larger study with larger number of participants that run longer
period of time is needed to show long term benefits and complications. Future researches in this
arena should focus on how sildenafil compares to other drugs that treat PAH. How it differs and
how its potential benefits compare to other drugs. These studies focused primarily on
hemodynamic measurements. It would be interesting to included patient feedback through
surveys on their quality of life improvement.
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